NanoTemper Boston User Meeting: Pushing the Boundaries of Biophysical Characterization
RegisterWhat you can expect
-
A talk from Stefan Duhr, NanoTemper CEO
A forward-looking talk on where biophysical characterization is headed, including emerging market trends and cutting-edge research directions.
-
Guided breakout sessions
Exchange workflow tips with fellow attendees and members of our Application Team in focused breakout discussions on Prometheus Panta, Monolith, and Dianthus.
-
Panel discussion
An open conversation with our esteemed guest speakers and leading voices of the NanoTemper Team.
-
Monolith Omni showcase
A show-and-tell featuring NanoTemper's newly launched Monolith Omni, a platform for in-solution binding kinetics that requires no immobilization and minimal sample consumption.
-
User talks & case studies
Hear directly from researchers using NanoTemper's technologies in their work.
-
Lunch & networking
Dedicated time to connect with fellow users and the NanoTemper team over lunch and posters.
-
10:00 AM – 10:20 AM
Arrival: Check-in, coffee, pastries, and casual networking
-
10:20 AM – 10:30 AM
Welcome address: Opening remarks from CEO Stefan Duhr, Ph.D.
-
10:30 AM – 10:50 AM
Talk by Derrick Meinhold, Ph.D., Director of Biophysics at WuXi AppTec
-
10:50 AM – 11:10 AM
Talk by Hossam Nada, Ph.D., Assistant Professor of Pharmaceutical Science at University of Massachusetts Lowell
-
11:10 AM – 11:20 AM
Short break
-
11:20 AM – 12:00 PM
Breakout discussions for exchanging workflow tips, guided by NanoTemper's Application Team members and divided into groups for Prometheus Panta, Monolith and Dianthus
-
12:00 PM – 01:30 PM
Complimentary lunch, casual networking, and posters
-
01:30 PM – 01:50 PM
Guest speaker 3 - tbd
-
01:50 PM – 02:10 PM
Guest speaker 4 - tbd
-
02:10 PM – 02:20 PM
Short break
-
02:20 PM – 02:40 PM
Talk by Stefan Duhr, NanoTemper CEO: "The Future of NanoTemper" — A forward-looking session on where biophysical characterization is headed
-
02:40 PM – 03:00 PM
Talk by Nathan Wallace, PhD: “Introduction to Monolith Omni” — Overview on the technology behind Monolith Omni: binding, kinetics, and stability in one workflow
-
03:00 PM – 03:20 PM
Omni Show & Tell — Sample experiment and data analysis
-
03:20 PM – 03:50 PM
Panel discussion — NanoTemper Team and guest speakers
-
03:50 PM – 04:00 PM
Closing remarks and raffle
Speaker information
Director of Biophysics, WuXi AppTec
Derrick is Director of US biophysics at WuXi AppTec and a drug discovery leader with 14 years of experience across pharma, biotech, and CRDMO enterprises focused on applying biophysics, biochemistry, and structural biology to hypothesis-driven decision-making in early discovery. Derrick has led and supported programs from target validation through clinical candidate selection, contributing to 19 clinical candidates. The US biophysics team within WuXi AppTec delivers interaction analysis, assay development, hit identification, and problem solving to support a wide array of drug modalities.
Field Application Scientist Manager, NanoTemper Technologies
With seven years of experience in biotech, Nathan Wallace is a Field Applications Scientist Manager at NanoTemper Technologies. He holds a PhD in Biology and is passionate about supporting cutting-edge drug discovery research through innovative biophysical characterization solutions. Outside of work, he enjoys spending time outdoors with his wife and dog.
CEO and Co-Founder, NanoTemper Technologies
Stefan Duhr co-founded NanoTemper Technologies in 2008, guided by a belief that complex biophysical science should be accessible, actionable, and built alongside the scientists who use it. He holds an M.Sc. in Biochemistry from Universität Witten/Herdecke and a doctorate in Physics from Ludwig-Maximilians-Universität München. Today, he leads NanoTemper’s mission to co-create tools that help drug developers move from data to confident decisions, faster.
Assistant Professor of Pharmaceutical Science, University of Massachusetts Lowell
Hossam Nada is a computational drug discovery researcher at UMass Lowell, working at the intersection of structural biology, cheminformatics, and biophysical validation. His research focuses on developing practical computational approaches for challenging drug discovery problems, including structure-guided ligand design, fragment-based screening, and the identification and optimization of small-molecule binders. He is a co-author of LigandForge, a web-based platform designed to support synthesis-aware de novo ligand generation and lead optimization.